Kyntra Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary

Kyntra Bio

13/08/2026 22:02

Kyntra Bio, Inc. KYNB.OQ reported a quarterly adjusted loss of $4.69​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.88.  The mean expectation of three analysts for the quarter was for a loss of $3.18 per share. Wall Street expected results to range from $-3.62 to $-2.92 per share.
Revenue rose 209.3% to $-1.47 million from a year ago; analysts expected $2.01 million. 
Kyntra Bio, Inc.'s reported EPS for the quarter was $2.96​.
The company reported quarterly net income of $11.97 million.
Kyntra Bio, Inc. shares had fallen by 6.0% this quarter and lost 19.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 2.7% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Kyntra Bio, Inc. is $35.00, about 79.7% above its last closing price of $7.10
This summary was machine generated from LSEG data August 13 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-3.18
-4.69
Missed
Mar. 31 2026 
-3.35
-3.76
Missed
Dec. 31 2025 
-3.88
-3.61
Beat
Sep. 30 2025 
-4.00
-3.25
Beat